The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
Concerns about a potential finasteride ban in the EU, possibly affecting the US, are discussed. Users doubt a ban, citing its widespread use and suggest alternatives like minoxidil and dutasteride.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
Scalp massage significantly reduced hair loss for the user, who had been using finasteride without improvement. The user attributes the reduction in hair loss to the massage rather than the medication.
PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.
Switching from liquid to foam Minoxidil to avoid scalp irritation, with a method to melt the foam for easier application. Users discuss alternatives and personal experiences with Minoxidil, including issues with propylene glycol and different application methods.
Volume boost shampoos, specifically Schwarzkopf Professional Bonacure Collagen Volume Boost Micellar Shampoo, may potentially impact hair due to creatine's effect on DHT. The user likes the shampoo for its gentle nature and thickening effect but is concerned about long-term use.
The conversation discusses how to use fluridil/topilutamide with other hair loss treatments like liquid minoxidil and CB-03-01, considering fluridil's hydrophobic nature and potential degradation with water. The user questions the necessity of washing hair only once per week as suggested by the manufacturer.
Buzzing hair can improve mental health and make applying treatments like Minoxidil and microneedling easier. It helps with self-acceptance and reduces the impact of hair loss on appearance.
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.
The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.
PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.
The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.
Scalp Botox may help hair loss by relaxing muscles and increasing blood flow, potentially benefiting conditions other than androgenetic alopecia. DHT affects hair follicles differently, causing tension and hair loss in some areas but not others.
Eucapil, containing fluridil, is used for hair loss but has impractical packaging. Some users find it effective for maintenance, while others suggest alternatives like anageninc with pyrilutamide.
PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.
People with hair loss experience emotional struggles and body dysmorphia. Treatments like minoxidil, finasteride, and dutasteride are used, but results vary and can take time.
A new alcohol-free, propylene glycol-free topical finasteride foam is available for prescription in Canada and the USA, offering a cleaner alternative for hair loss treatment. The product also offers a combination of 0.1% finasteride with 5% minoxidil and aims to be affordable and less irritating for sensitive scalps.
The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.
A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.
TE (telogen effluvium) is often misunderstood and is triggered by severe stress or trauma, not minor daily inconveniences. Most hair loss cases are due to male pattern baldness (AGA), and treatments like Minoxidil and finasteride can help.
The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.
People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.
The conversation discusses concerns about a new rule affecting orders of hair loss treatments like Minoxidil, finasteride, and RU58841. Users are worried about the impact on their ability to obtain these products.
The conversation discusses hair loss treatments, specifically the use of RU58841 by individuals who did not respond to dutasteride. Users share experiences with maintaining hair using RU58841 and mention trying pyrilutamide and the upcoming availability of pp405.
A 26-year-old male is experiencing hair loss and is interested in Botox scalp injections as a treatment, preferring it over finasteride due to fewer hormonal impacts. He seeks recommendations for US doctors offering this treatment and feedback from those with experience.
The conversation discusses hair loss concerns, specifically traction alopecia and hair loss from acne. It mentions that sleeping on one side is unlikely to cause traction alopecia.
The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.